United States· US:0002-8905_246fceb3-0f60-4bd7-8f06-4f34537f5d95
TALTZ
A medicinal product containing ixekizumab, registered in United States by Eli Lilly and Company.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ixekizumab
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1100028905111 SYRINGE in 1 CARTON (0002-8905-11) / 1 mL in 1 SYRINGE (0002-8905-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ixekizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTALTZEli Lilly and Company (Ireland) Limited, Kinsale
- IrelandTaltz 40mg Solution for injectionEli Lilly Kinsale Limited
- SwitzerlandTaltz 40 mg, solution injectable en seringue préremplieEli Lilly (Suisse) SA
- FinlandTaltzEli Lilly and Company (Ireland) Limited
- BelgiumTaltz 40 mgEli Lilly and Company (Ireland)
- IcelandTaltzEli Lilly and Company (Ireland) Limited
- NetherlandsTaltz 40 mg oplossing voor injectie in voorgevulde injectiespuitEli Lilly and Company (Ireland) Limited
- SwedenTaltz 40 mg Injektionsvätska, lösning i förfylld sprutaEli Lilly And Co (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Taltz
- Liechtenstein · Taltz
- Norway · Taltz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c1a763ff-154c-47b0-bec1-e6eb2ca543e3 GET /v1/drugs/c1a763ff-154c-47b0-bec1-e6eb2ca543e3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0002-8905_246fceb3-0f60-4bd7-8f06-4f34537f5d95",
"productndc": "0002-8905",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "IXEKIZUMAB",
"proprietary_name": "TALTZ",
"active_ingred_unit": "mg/.5mL",
"application_number": "BLA125521",
"marketing_category": "BLA",
"nonproprietary_name": "ixekizumab",
"start_marketing_date": "20160322",
"active_numerator_strength": "40"
}See everything about ixekizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.